OLON SUCCESSFULLY COMPLETED ALL THE DEVELOPMENT PHASES AND FILING PROCEDURE FOR ZANUBRUTINIB
Olon enriched its API GENERIC PORTFOLIO WITH THIS PROMISING API, REPRESENTING THE PARTNER OF CHOICE FOR OUR PHARMA CUSTOMERS, WHO CAN SUPPORT THE MOST COMPETITIVE TIME TO MARKET.
Thanks to investment in Research, Olon’s API portfolio has grown significantly over the years, with considerable diversification in the areas of oncology.
Olon’s APIs are intended to treat solid tumors and blood cancers, such as lymphomas and lung, liver, and breast cancer. The Olon portfolio includes seven nibs
Zanobrutinib is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.
Our portfolio here: Olon portfolio